Novo Nordisk Buys New Hampshire Production Plant
News Aug 28, 2014
The facility was established in 1989, expanded in 2003-2006 and acquired by Olympus Biotech in 2011. It has been used primarily for mammalian cell manufacturing until production was phased out earlier this year.
Novo Nordisk intends to use the facility for production of active pharmaceutical ingredients primarily for its portfolio of biopharmaceuticals. Some of the plant's former employees have been offered jobs, which initially will focus on planning of the future plant setup. Final plans will determine potential and timing for future staffing increases.
Novo Nordisk and Olympus Biotech have agreed not to disclose the terms of the acquisition.
Symmetry-breaking Method Opens Way for Bioactive CompoundsNews
EPFL chemists have developed a new catalytic method for symmetry breaking. Published in Angewandte Chemie, the method can help synthesize important building blocks for bioactive compounds such as anticancer drugs.READ MORE
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.